Krebs Biochemicals and Industries Ltd

Krebs Biochemicals & Industries Ltd exhibits a highly leveraged capital structure, with total liabilities of INR 3,152.74 million and total equity of INR -1,462.39 million, resulting in a negative debt-to-equity ratio of -1.45. The company's liquidity position is weak, as evidenced by a current ratio of 0.1, indicating that current assets are insufficient to cover current liabilities. Free cash flow is negative at INR -238.13 million, and operating cash flow is also negative at INR -78.91 million, suggesting ongoing cash flow challenges. Profitability metrics are mixed. The company reports a gross profit of INR 192.33 million, but operating income is negative at INR -217.19 million, and net income is INR -269.39 million. Return on equity is positive at 18.42%, but return on assets is negative at -15.94%, indicating that the company is not generating returns sufficient to cover its asset base. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided. This lack of diversification increases exposure to sector-specific risks. The company's product portfolio includes Androstenedione, Lovastatin, and Simvastatin, with several products in pilot or R&D stages, including Amlodipine, Cetirizine, and Orlistat. Growth trajectory is uncertain. The company has not provided forward-looking revenue guidance, and historical data shows a decline in profitability. Capital expenditures are negative at INR -35.63 million, suggesting a reduction in investment in new capacity or technology. The absence of clear growth drivers and the negative operating cash flow raise concerns about the company's ability to sustain operations without external financing. Risk factors include liquidity constraints, with net cash negative after subtracting total debt, and a high debt load. The company's dilution risk is currently low, but the negative equity position and ongoing losses could necessitate future equity raises, which would dilute existing shareholders. The risk assessment indicates a medium liquidity risk, with no immediate signs of dilution pressure. Recent events include the disclosure of financial results showing continued losses and negative cash flows. No significant regulatory or operational events were reported in the latest filings. The company's reliance on contract manufacturing for large pharmaceutical companies exposes it to client concentration risk, though specific client names are not disclosed.